StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about MAZE. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $26.86 | $26.43 | -1.60% | 0.4M |
| 05-15 | $25.95 | $25.56 | -1.50% | 0.4M |
| 05-18 | $25.54 | $24.50 | -4.07% | 0.6M |
| 05-19 | $24.29 | $24.46 | +0.70% | 0.5M |
| 05-20 | $24.73 | $25.03 | +1.21% | 0.3M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q2 2025 2025-06-30 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 |
|---|---|---|---|---|
Revenue | $20.00M | $0.00 | $167.50M | $167.50M |
Operating Income | $-26.55M | $-71.88M | $57.59M | $87.31M |
Net Income | $-24.21M | $-33.68M | $52.23M | $81.81M |
EPS (Diluted) | $-0.45 | $-1.83 | $1.25 | $2.67 |
Total Assets | $419.71M | $303.52M | $240.54M | Not available |
Total Liabilities | $78.01M | $41.28M | $43.64M | Not available |
Cash & Equivalents | $198.77M | $264.54M | $196.81M | $149.61M |
Free Cash Flow OCF − CapEx | $-39.21M | $-60.26M | $74.81M | $97.86M |
Shares Outstanding | 49.74M | 43.85M | 2.45M | 3.39M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.